Aurinia Pharmaceuticals

Hope springs for April inhibition
EP Vantage
Tue, 06/13/23 - 10:27 am
Novartis
Chinook Therapeutics
April inhibition
M&A
Vera Therapeutics
Otsuka
RemeGen
Alpine Immune Sciences
Akso Biopharmaceutical
Aurinia Pharmaceuticals
3 Biotechs That Might Get Bought Out in 2023
Motley Fool
Wed, 04/26/23 - 05:41 pm
M&A
Madrigal Pharmaceuticals
Amylyx
Aurinia Pharmaceuticals
Aurinia Pharma, Sun Pharma enter into settlement agreement for dry eye disease drug
Medical Dialogues
Wed, 01/4/23 - 09:41 am
Aurinia Pharmaceuticals
Sun Pharma
dry eye disease
Cequa
Two Aurinia execs are out — and CRISPR’s operations chief isn't far behind
Endpoints
Sun, 10/30/22 - 04:05 pm
Aurinia Pharmaceuticals
CRISPR Therapeutics
Why Aurinia Pharmaceuticals Tumbled Despite Its 'Aggressive' 2022 Outlook
Investors Business Daily
Thu, 03/3/22 - 11:36 pm
Aurinia Pharmaceuticals
earnings
Lupkynis
What to Expect From Biogen's $2.3 Billion Shopping Spree
Motley Fool
Sat, 02/12/22 - 11:47 pm
Biogen
M&A
Aurinia Pharmaceuticals
Biohaven
Biotech investors pray for a takeover miracle
EP Vantage
Fri, 01/14/22 - 11:09 am
M&A
biotech
Amylyx Pharmaceuticals
Arena Pharmaceuticals
AstraZeneca
Aurinia Pharmaceuticals
Biogen
Biohaven
Bristol Myers Squibb
Eli Lilly
GSK
Merck
Novartis
Novo Nordisk
Pfizer
Sanofi
Is Bristol Myers Squibb's Reported Acquisition of Aurinia a Smart Move?
Motley Fool
Sun, 11/7/21 - 10:55 pm
Bristol Myers Squibb
Aurinia Pharmaceuticals
M&A
What Novartis could buy with its windfall
EP Vantage
Fri, 11/5/21 - 09:40 am
Novartis
M&A
Roche
Sandoz
Aurinia Pharmaceuticals
Alnylam
Exelixis
Incyte
Eisai
Genmab
Here's Why Bristol Myers Squibb Can't Miss Out on Aurinia Pharmaceuticals
Motley Fool
Wed, 11/3/21 - 10:39 am
Bristol Myers Squibb
Aurinia Pharmaceuticals
M&A
Acquisition Rumors Continue to Circulate Around Aurinia as GSK Denies Interest
BioSpace
Mon, 11/1/21 - 11:21 pm
GSK
Aurinia Pharmaceuticals
M&A
2 Biotech Stocks That Could Go Parabolic This Week
Motley Fool
Mon, 10/25/21 - 10:57 am
biotech
biotech stocks
Aurinia Pharmaceuticals
M&A
Ocugen
Covaxin
vaccines
COVID-19
Bristol Myers Squibb, after passing on Acceleron, now eyes Aurinia takeout
Fierce Pharma
Sun, 10/24/21 - 10:40 pm
Bristol Myers Squibb
Acceleron
M&A
Aurinia Pharmaceuticals
Eight Months After First FDA Approval, Aurinia Picks Up Two More Candidates
BioSpace
Tue, 08/17/21 - 10:40 pm
Aurinia Pharmaceuticals
autoimmune disease
Thunderbolt Pharma
M&A
Pfizer's CEO Wants to Go Shopping: 3 Potential Companies on His Radar
Motley Fool
Thu, 08/5/21 - 10:57 am
Pfizer
M&A
Blueprint Medicines
Aurinia Pharmaceuticals
Atea Pharmaceuticals
Fortunes diverge for solo drug launchers
EP Vantage
Tue, 05/11/21 - 11:01 am
drug launches
Intra-Cellular Therapies
Biocryst
Horizon Therapeutics
Karyopharm Therapeutics
Blueprint Medicines
Zogenix
Esperion
Epizyme
Aurinia Pharmaceuticals
Global Blood Therapeutics
Catalent signs on to produce Aurinia's newly approved lupus nephritis drug
Fierce Pharma
Mon, 02/22/21 - 10:46 am
Catalent
Aurinia Pharmaceuticals
lupus nephritis
Lupkynis
CDMOs
Here’s Why the Approval of Lupkynis Has Biotech Investors Buzzing
Xtalks
Mon, 02/1/21 - 10:52 am
FDA
Aurinia Pharmaceuticals
Lupkynis
voclosporin
lupus nephritis
After losing race for first to market in lupus nephritis, Aurinia taps Otsuka for voclosporin licensing pact abroad
Endpoints
Thu, 12/17/20 - 06:18 pm
Aurinia Pharmaceuticals
lupus nephritis
GSK
Otsuka
Benlysta
Three Biotechs Shutter Clinical Programs After Futility Analysis or Failed Trials
BioSpace
Tue, 11/3/20 - 09:29 pm
Jounce Therapeutics
vopratelimab
Santhera
vamorolone
Puldysa
Aurinia Pharmaceuticals
FOS

Pages